Urinary tract infections occupy a leading place among nephrological pathology and infectious diseases in general. The article deals with the aetiology and key stages of the pathogenesis of urinary system lesions. The mai...
Limitations of possible correction for potentially modified factor the risk of death of patients, who are on renal replacement therapy, by techniques of hemodialysis were studied. The conclusions about the possibility of...
Metabolic syndrome (MS) is a combination of a disorder of carbohydrate metabolism, abdominal obesity, dyslipidemia and arterial hypertension. Studies show that there is a close relationship between MS and chronic kidney...
National Institute for Health and Care Excellence (NICE) June 14, 2016 – Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR) External Web Site Policy: The U.S. Food and Drug Administration (FDA) ha...
The main problems of acute kidney injury (AKI) are considered. The necessity of introduction of the AKI concept into the practice of national health care is justified. Specific recommendations for the diagnosis, monitori...
Ciprofloxacin in Urinary Tract Infection Treatment
Urinary tract infections occupy a leading place among nephrological pathology and infectious diseases in general. The article deals with the aetiology and key stages of the pathogenesis of urinary system lesions. The mai...
Correction of Potentially Modified Risk Factors in Hemodialysis Treatment: Standards of Therapy and Individualized Programs of Dialysis
Limitations of possible correction for potentially modified factor the risk of death of patients, who are on renal replacement therapy, by techniques of hemodialysis were studied. The conclusions about the possibility of...
Metabolic syndrome and the risk of chronic kidney disease
Metabolic syndrome (MS) is a combination of a disorder of carbohydrate metabolism, abdominal obesity, dyslipidemia and arterial hypertension. Studies show that there is a close relationship between MS and chronic kidney...
Guideline Summary NGC (2016): Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
National Institute for Health and Care Excellence (NICE) June 14, 2016 – Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR) External Web Site Policy: The U.S. Food and Drug Administration (FDA) ha...
National Guidelines «Acute Kidney Injury: Basic Principles of the Diagnosis, Prevention and Treatment (2015)» Part I
The main problems of acute kidney injury (AKI) are considered. The necessity of introduction of the AKI concept into the practice of national health care is justified. Specific recommendations for the diagnosis, monitori...